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Strengths and limitations of this study
 ► This pragmatic randomised controlled feasibility tri-
al examined ‘My Breathing Matters’ (MBM), a digital 
asthma self- management intervention that support-
ed both pharmacological and non- pharmacological 
management of asthma symptoms.
 ► MBM was developed using theory, evidence and 
person- based approaches, and compared with 
standardised usual care (a booklet) with successful 
blinding and randomisation.
 ► Not all patients engaged with the intervention, and 
although numeric improvements in patient- reported 
asthma outcomes were larger in the active arm, im-
provements were observed in both arms.
AbStrACt
Objective To assess the feasibility of a randomised 
controlled trial (RCT) and acceptability of an asthma 
self- management digital intervention to improve asthma- 
specific quality of life in comparison with usual care.
Design and setting A two- arm feasibility RCT conducted 
across seven general practices in Wessex, UK.
Participants Primary care patients with asthma aged 18 
years and over, with impaired asthma- specific quality of 
life and access to the internet.
Interventions ‘My Breathing Matters’ (MBM) is a digital 
asthma self- management intervention designed using 
theory, evidence and person- based approaches to provide 
tailored support for both pharmacological and non- 
pharmacological management of asthma symptoms.
Outcomes The primary outcome was the feasibility of 
the trial design, including recruitment, adherence and 
retention at follow- up (3 and 12 months). Secondary 
outcomes were the feasibility and effect sizes of specific 
trial measures including asthma- specific quality of life and 
asthma control.
results Primary outcomes: 88 patients were recruited 
(target 80). At 3- month follow- up, two patients withdrew 
and six did not complete outcome measures. At 12 
months, two withdrew and four did not complete outcome 
measures. 36/44 patients in the intervention group 
engaged with MBM (median of 4 logins, range 0–25, IQR 
8). Consistent trends were observed to improvements in 
asthma- related patient- reported outcome measures.
Conclusions This study demonstrated the feasibility 
and acceptability of a definitive RCT that is required to 
determine the clinical and cost- effectiveness of a digital 
asthma self- management intervention.
trial registration number ISRCTN15698435.
IntrODuCtIOn
Asthma prevalence in the UK is among the 
highest in the world at nearly 6% of the UK 
adult population, comprising 5.4 million 
people, with the most managed in primary 
care. Although hospital admission and 
mortality rates for asthma improved from 
1970 to 2000, these improvements have since 
stalled.1 Surveys of asthma symptoms and 
health status impairment show that subop-
timal control is common and that the majority 
of people with asthma in the UK frequently 
experience potentially avoidable symptoms 
and quality of life (QOL) impairment.2
Proactive self- management of asthma has 
been convincingly shown to improve clin-
ical outcomes and have been advocated in 
guidelines for 25 year.3 Guidelines are not 
always well implemented4 and consequently 
some people with asthma do not receive 
evidence- based interventions that are known 
to impact positively on outcomes. Recent 
large- scale systematic reviews demonstrated 
that supported asthma self- management can 
reduce healthcare utilisation and increase 
asthma control, without increasing health-
care costs.5 6 For example, people with asthma 
without a management plan are four times 
more likely to have an asthma attack needing 
emergency care in hospital, yet only 44% of 
people with asthma in the UK report having 
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a self- management plan.7 Self- management recom-
mendations for asthma have also encompassed non- 
pharmacological strategies to improve control. These 
include lifestyle interventions, such as smoking cessation, 
allergen avoidance, weight reduction in those with obesity 
and breathing retraining interventions.8
Digital interventions (DIs) are increasingly recognised 
as a possible approach to achieve the aims of supporting 
chronic diseases, such as asthma. DIs can be convenient, 
easily accessed and may provide cost- effective tools by auto-
mating routine aspects of patient education, monitoring 
and support.9 There is accumulating evidence that DIs 
are feasible and may be effective in the context of asthma. 
The Self- Management of Asthma Supported by Hospitals, 
Information and communication technology, Nurses 
and General practitioners (SMASHING) trial compared 
usual care with web- based educational resources, self- 
monitoring and automated feedback on medication 
titration, plus some group and email nurse support for 
patients with asthma. After 12 months, the intervention 
group had a better QOL and lung function and more 
symptom- free days, at no extra cost.10 The Randomised 
trial of an Asthma Internet Self- management Interven-
tion (RAISIN) pilot trial indicated that self- management 
interventions that included non- pharmacological 
(behavioural and psychological) components could be 
effective at improving QOL and asthma control, with 
improvements to ‘reach’ and response rate, by catering to 
patients with mild asthma but impaired QOL.11 A recent 
systematic review and meta- analysis indicated that self- 
management DIs may be able to improve asthma control 
and reduce asthma- related QOL impairment12; however, 
there is limited evidence of benefit for other outcomes 
and larger confirmatory trials are required.
In the current randomised controlled feasibility trial, 
we developed and evaluated a digital self- management 
intervention, that incorporated pharmacological and 
non- pharmacological self- management support for adults 
in primary care with impaired asthma- specific QOL (‘My 
Breathing Matters’; MBM), using evidence, theory and 
person- based approaches13 and in line with Medical 
Research Council (MRC) guidance for developing and 
evaluating complex interventions.14
Aim
The aim of the MBM study was to assess the feasibility of a 
trial to evaluate a DI in primary care to improve QOL and 
other clinical outcomes (such as asthma control, health 
resource use and lung function) of people with asthma, 
in comparison to usual care (with provision of standard 
patient information materials produced by the charity 
Asthma UK).
research objectives
1. To assess feasibility of trial procedures including re-
cruitment strategy, eligibility criteria, consent, with-
drawal, randomisation and blinding.
2. To assess feasibility of the MBM DI including usage and 
engagement.
3. To assess feasibility of data analysis, including data 
collection, data quality and management of trial data 
across trial endpoint measures to inform sample size 
calculations for a larger phase 3 randomised con-
trolled trial (RCT).
MethOD
Design
We conducted a pragmatic feasibility RCT of the MBM DI 
in primary care.
Setting
Eligible participants were identified from seven general 
practices from the Wessex, UK primary care research 
network to facilitate recruitment of people with varied 
socioeconomic status. To ensure we evaluated the inter-
vention across a spread of socioeconomic deprivation, 
practices were purposively selected to be both rural (n=4) 
and urban (n=3), with mean practice deprivation index 
of 20.60% (SD 10.5); practice socioeconomic deprivation 
deciles=2, 4, 4, 5, 8, 10, 10, in which lower deciles indicate 
more deprivation.15
Participants
Patients were included in the trial if they were aged 18 
years or more, had physician- diagnosed asthma in their 
medical record, had received one or more antiasthma 
medication prescription in the previous 12 months, had 
impaired asthma- related health status (Asthma Quality 
of Life Questionnaire (AQLQ) score of less than 5.5 as 
assessing using a self- completed postal questionnaire), 
provided informed consent, were able to understand 
English and had access to the internet.
They were excluded from the trial if: (1) their general 
practitioner (GP) considered it inappropriate for them 
to take part (such as having an additional terminal 
condition), (2) they were attending a secondary care 
asthma clinic, or they were receiving either maintenance 
oral corticosteroids or injected biological treatments 
to control their asthma, (3) they were diagnosed with 
Chronic Obstructive Pulmonary Disease (COPD), (4) 
they had a household member already enrolled on the 
study or (5) they were judged by the research nurse to 
have ‘unstable asthma’ according to the clinical assess-
ment and spirometry data at the baseline assessment (in 
which case they were referred back to their GP), or were 
diagnosed with ‘difficult asthma’ defined by the British 
Thoracic Society (BTS).
recruitment
Electronic searches of the computerised primary care 
medical record were conducted, and records screened 
by GP to remove ineligible participants. Invitation letters, 
study information sheets, consent forms screening ques-
tionnaires (Mini AQLQ16) and freepost return envelopes 
were posted to the participants who returned them if they 
copyright.
 o
n
 January 13, 2020 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032465 on 12 November 2019. Downloaded from 
3Ainsworth B, et al. BMJ Open 2019;9:e032465. doi:10.1136/bmjopen-2019-032465
Open access
were interested in taking part. Patients who met screening 
criteria (AQLQ score of less than 5.5) were contacted by 
research team staff and attended a baseline appointment 
at their practice with a trained research nurse. Recruit-
ment began in March 2017 and was completed in August 
2017.
Sample size
The target for this trial was to recruit 80 patients overall (40 
per arm), in order to assess primary feasibility outcomes 
and to assess intervention engagement and acceptability.
randomisation and blinding
After completing outcome measures at their baseline 
appointment participants were randomised (block rando-
misation stratified by an average primary care AQLQ score 
(4.3) taken from a previous trial using the same inclu-
sion criteria8). Information packs were given to partici-
pants after randomisation with instructions on signing 
up to MBM (if randomised to intervention group) or just 
usual care materials (if randomised to control). Research 
nurses conducting baseline appointments were blinded 
throughout the study until the final questionnaire that 
was only delivered to the intervention group.
Interventions
Intervention group: usual care with MBM and asthma UK booklet
Patients in the intervention group continued to receive 
usual care but were also given a code that allowed free 
unlimited access to MBM. MBM is a digital asthma 
self- management intervention that supports asthma 
self- management using both pharmacological and non- 
pharmacological approaches, developed using the Life-
Guide Software17 and described below according to the 
Template for Intervention Description and Replication 
(TIDieR) checklist.18 A demonstration version of the 
intervention is available here: http://www. mybreathing-
matters. co. uk. After signing up and completing quality- 
of- life- related self- monitoring questions, patients were 
offered tailored advice that directed them towards specific 
pharmacological or non- pharmacological sections of 
the online intervention. The pharmacological section 
provided information on different medication classes 
and inhalers, the use of personalised asthma action plans 
(PAAPs), encouraged medication adherence and gave 
information to facilitate and inform an effective asthma 
review with their GP. Pharmacological content was 
initially based on ‘Living Well with Asthma’, an asthma 
self- management intervention that previously demon-
strated feasibility for self- management11 19 and was devel-
oped in collaboration with people with asthma and with 
input from Asthma UK (a national asthma charity). This 
section was designed to answer common concerns about 
medication, incorporating a strategy described as ‘the 
4- week medication challenge’ that encouraged partici-
pants to realise the benefits of adherence to regular medi-
cation, by self- monitoring their symptoms during 4 weeks 
of continuous inhaler use. The non- pharmacological 
support included sections on a number of strategies to 
improve asthma control, such as breathing retraining, 
stress reduction and additional healthy lifestyle resources 
(physical activity, weight reduction, hand hygiene and 
smoking cessation). Optional nurse support was available 
by Asthma UK who provide a dedicated nurse helpline 
that was advertised through the intervention.
The intervention was developed using the person- 
based approach,20 which places patients at the heart of 
the development process. Evidence from the primary 
mixed- methods research (such as Morrison et al19) and 
qualitative and quantitative reviews was used to develop 
guiding principles. A prototype intervention was piloted 
using ‘think aloud’ interview studies, in which patients 
with asthma used prototype versions of the MBM website 
and provided feedback on intervention acceptability and 
feasibility as they used it. In 46 interviews with 30 patients 
(purposively selected across a range of age and gender), 
the intervention was iteratively modified and updated to 
address patient feedback until participants indicated no 
further modification was required, confirming the inter-
vention was as acceptable and engaging as possible for 
(see Yardley et al21 for more details).
Due to the digital nature of the intervention, partici-
pants could engage with components of the intervention 
as much or as little as they wished. Tailored advice was 
offered according to participants’ preference to find out 
more about pharmacological or non- pharmacological 
self- management techniques (patients selected a check 
box option of ‘I’d like to find out more about how my 
asthma could be helped by (1) making the most of my 
asthma medicine or (2) ‘non- medicine’ ways to help 
my breathing.’), with automated reminders whenever 
patients had not accessed the intervention for several 
weeks, or when content was made available that they had 
not previously seen. The intervention was not modified 
during the study.
Intervention usage was monitored through digital 
usage metrics (reported below). Non- engagement with 
the website was not addressed, in line with the pragmatic 
nature of the feasibility study. Participants were sent one 
email and received one phone call, in which they were 
offered technical support if they had not logged onto the 
intervention at all for 1 month following their baseline 
appointment.
Control group: usual care with asthma UK booklet
To provide ‘good- quality’ usual care to participants allo-
cated to this arm, as well as usual care from their practice, 
participants were given an Asthma UK booklet ‘Live Well 
with Asthma’ at their baseline appointment. The booklet 
was created by a multidisciplinary team and expert 
patients, and aimed to provide essential information and 
advice to enable effective self- management to occur. It 
is available to anyone via the Asthma UK website.22 The 
booklet was provided in a hard copy and provided infor-
mation about asthma symptoms and triggers, medication 
adherence and usage techniques, PAAPs and support 
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from families. The booklet also advertised the Asthma UK 
support line. Booklet usage was not monitored.
Outcome measures
In line with objectives, trial outcomes are reported below 
as (1) feasibility outcome measures, (2) intervention 
usage outcome measures and (3) trial endpoint measures 
to inform a larger trial.
Feasibility outcome measures
Primary outcomes for the trial were descriptive, exam-
ining trial design and intervention feasibility and accept-
ability. These outcomes included patient recruitment, 
patient withdrawals and follow- up retention.
Internet usage and engagement measures
Usage of the intervention included access to specific 
intervention components and frequency of engagement 
with individual components. These data were collected 
using the LifeGuide software.
Endpoint measures
It is envisaged that the likely primary outcome measure 
or measures in a full trial would include validated asthma- 
specific patient- reported outcome measures evaluating 
symptom control and QOL, with additional secondary 
outcomes measuring health resource use, psychological 
measures and a health economic analysis. Data to generate 
hypotheses (and perform sample size calculations with 
which to test them) were collected in the following trial 
endpoints at baseline, 3 and 12 months:
 ► Asthma- specific QOL. Measured using the Mini- 
AQLQ16, a 15- item 7- point scale in which higher 
scores represent higher QOL.
 ► Asthma control. Measured using the Asthma Control 
Questionnaire (ACQ23), a 7- item 7- point scale in 
which higher scores indicate worse asthma control.
 ► Health- related QOL. Measured using the EuroQol 
Five Dimensional Quality of Life (EQ- 5D- 5L),24 in 
which participants select their functioning level across 
five dimensions (immobility, self- care, usual activities, 
pain and discomfort, and anxiety and depression) on 
a 5- point scale, with higher scores indicating greater 
problems with functioning.
 ► Health- related capability. Measured using the Icepop 
Capability measure for Adults (ICECAP- A25), in which 
participants select their capability across five dimen-
sions (stability, enjoyment, achievement, attachment 
and autonomy) on a 4- point scale, with higher scores 
indicating better capability.
 ► Anxiety and depression. Measured using the Hospital 
Anxiety and Depression Scale (HADS26), a 12- item 
questionnaire in which higher scores on depression 
and anxiety subscales indicate higher anxiety across 
two subscales (anxiety and depression).
 ► Enablement. Measured using a modified version of 
the patient enablement instrument (PEI27) that has 
been validated in previous RCTs.28 The modified 
PEI is a 7- point scale consisting of six items, in which 
higher scores indicate more enablement.
 ► Patient satisfaction. Measured by asking patients 
whether they saw any benefits or disadvantages to 
using MBM, and whether they would recommend it 
to friends and family based on the National Health 
Service (NHS) friends and family test (FFT).29
 ► Patient burden was measured using a specifically 
developed questionnaire exploring time and costs via 
self- report based on Burden of Treatment Theory.30 
The questionnaire consisted of four questions with 
descriptive responses that explored whether new 
programmes were signed up to (such as gym member-
ship, yoga/meditation) and the financial burden of 
doing so (see online supplementary appendix 1).
Physiological measures of lung function were taken 
at baseline and 12- month appointments: forced expira-
tory volume (FEV1), ratio of FEV1 to forced vital capacity 
(FEV1/FVC) and peak expiratory flow rate (PEFR).
At 12- month follow- up, we also monitored health 
resource use GP consultations, Accident and Emergency 
Department (A&E) visits at, hospital admissions, asthma 
medication use and use of antibiotics for chest infections 
using GP practice patient notes.
Healthcare utilisation data were collected via retro-
spective notes review conducted by practice staff. Staff 
were provided with a template for reviewing data, and an 
instruction manual to ensure correct data were provided. 
Initial notes reviews were completed within two months 
from completion of the primary data collection. Nine 
patients (10% of the total patients in each practice) were 
also reviewed by research nurses to assess data quality.
Patient and public involvement
Asthma UK was involved in the initial project proposal 
and supported the project throughout. Patient and public 
representatives (recruited with help from Asthma UK) 
participated in intervention development (providing feed-
back on prototype versions of the intervention, attending 
study management meetings, helping to develop trial 
materials and procedures and discussing responses to 
participant feedback). Asthma UK is involved in dissem-
ination of this research and ongoing projects related to 
the research.
Data analysis
Primary analysis of the study was a description of key feasi-
bility outcomes including patient eligibility, recruitment 
rates, withdrawals, 3 and 12 months follow- up response 
rates and DI usage, as reported in the trial protocol (see 
online supplementary file 1).
Descriptive statistics were used to identify any floor or 
ceiling effects. For continuous measures, means, SD and 
95% CIs were reported at baseline, 3 and 12 months for 
each group, as well as for the sample as whole.
Exploratory analysis explored group differences in 
continuous primary endpoint measures (AQLQ, ACQ, 
HADS and PEI) using linear regression models that 
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Figure 1 Study CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials.
controlled for baseline values. Participants were analysed 
in the group to which they had been randomised and 
comprised complete cases only.
Proportions of patients achieving a minimal clinically 
important difference (MCID) were described for asthma 
QOL (the AQLQ MCID is 0.516).
Sensitivity analysis explored missing data at 3 and 12 
months.
Healthcare utilisation outcomes were explored using a 
negative binomial model of group count data.
Health economic analysis was descriptive, reporting esti-
mates of cost and outcomes measures and baseline and 
follow- up. The completeness and suitability of EQ- 5D- 5L 
and ICECAP were compared as was the appropriateness 
of the resource use, and time and cost tools developed 
for the study.
Intervention engagement was descriptive.
reSultS
recruitment and retention
Six practices were initially recruited and after monitoring 
recruitment rates a seventh practice added. In this addi-
tional practice, only half of the list (randomly selected) 
were offered participation in the study to avoid over 
recruiting. Across the seven practices, 68 478 patients 
were assessed for eligibility with 3199 meeting initial 
eligibility criteria (asthma diagnosis, >1 asthma medicine 
prescription in last 12 months, screened by practice). 266 
patients completed postal screening measures before the 
recruitment period finished, of whom 125 were eligible 
to take part (impaired asthma- related QOL, AQLQ score 
less than 5.5). Ninety patients responded to further 
contact. Two patients did not attend their baseline 
appointment leaving a final sample of 88 patients (inter-
vention n=44, usual care n=44) who were recruited into 
the study (13.5 per practice) and were randomised over a 
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5- month period. Figure 1 presents the study Consolidated 
Standards of Reporting Trials diagram.
During the study, two patients withdrew before 3- month 
follow- up and two before 12- month follow- up. All were 
in the intervention group. Patients withdrew for several 
reasons including lack of time (n=1), illness (n=1), death 
of family member (n=1) and lack of perceived benefit 
(n=1). Three of four participants who withdrew had 
used the intervention, one had not. One participant was 
withdrawn from the study prior to 12- month follow- up 
they were no longer eligible (ie, they were referred to 
secondary care).
Follow- up rates at 3 months were 91% (80/88; inter-
vention: 36/44, control 44/44). Six (7%) patients did not 
complete 3- month follow- up measures but did not with-
draw (all in intervention group).
At 12 months, 91% of participants provided primary 
outcome data by attending a follow- up appointment or 
returning a postal questionnaire (80/88; intervention: 
37/45; control 43/43). 76% attended a baseline appoint-
ment and provided secondary clinical data (67/88). Four 
(5%) patients did not complete 12- month follow- up 
measures but did not withdraw (three in intervention 
group, one in usual care). None of these intervention 
participants had used the intervention. None of these 
patients responded to efforts to contact them by the study 
team.
Patient characteristics
Demographics and baseline characteristics of partici-
pants are presented in table 1 and were reasonably well 
balanced between arms across all measures.
Table 1 compares those lost to follow- up to those who 
remained in the study at 3 months in a sensitivity anal-
ysis. Those lost to follow- up were slightly more likely to be 
female, have a higher body mass index (BMI), a longer 
time since diagnosis, a lower AQLQ score, a higher 
HADS- A and HADS- D score and to be from a more 
deprived postal code.
Intervention usage and engagement
At 12- month follow- up, 36 (82%) patients in the interven-
tion arm had engaged with the intervention (at least 1 
log in). Patients logged in between 0 and 25 times to the 
intervention (median=4; IQR=8.25). Several patients also 
engaged with additional lifestyle modification interven-
tions including improving hand hygiene (n=2), weight 
loss (n=3), improving physical activity (n=3) and getting 
support from friends and family (n=5).
After the study, participants in the intervention group 
were asked ‘Do you think there were any benefits to 
using MBM?’. 12 of 36 (33%) reported ‘quite a bit/a 
large amount of benefit’, 19/36 (53%) reported ‘some 
benefit’ and 5/36 (14%) reported ‘very little benefit’. 
22 participants completed a free text box describing 
the advantages—benefits varied but included informa-
tion provision (such as ‘weight loss’, ‘dietary/exercise 
regimes’), medication adherence (such as asthma action 
plans, improved medication adherence), provision of 
non- pharmacological treatments (such as breathing exer-
cises and relaxation) and accessibility (such as ‘access to 
information quickly’). This is reported in more detail in a 
separately published process analysis.
Participants were also asked ‘Do you think there were 
any disadvantages to using MBM?’. 25 of 36 (69%) 
reported no disadvantages at all, 3 (8%) reported very 
few disadvantages, 8 (22%) reported some disadvantages 
and none reported quite a bit or a large amount of disad-
vantages. Thirteen participants completed a free- text 
box describing disadvantages, which included technical 
difficulties (such as not always accessible across different 
devices, difficulty logging in) and information specificity 
(such as not enough information, too many reminders, 
too few reminders). A final question asked how likely 
participants were to recommend MBM to friends or 
family. Sixteen participants (44%) were extremely likely 
to recommend it, 12 participants (33%) were likely, 
7 (19%) were neither likely nor unlikely and 1 was 
extremely unlikely (3%).
trial endpoint measures
The full data of the trial endpoints are set out in table 2.
Both the intervention group and control group 
improved from baseline to 3 and 12- month follow- up, 
with numerically larger improvements in the asthma- 
related patient- reported outcomes measuring QOL and 
symptom control (AQLQ and AQC) at both time points; 
one or both these measures are anticipated to be the 
primary outcome of a subsequent fully powered study.
At the 3- month evaluation, patients in the interven-
tion group who completed 3- month follow- up measures 
(n=36) had mean improvement in asthma- related QOL 
(AQLQ score) of 0.53 (95% CI 0.31 to 0.75), and in the 
control group of 0.52 (95% CI 0.30 to 0.74), with the 
between- group difference (controlling for baseline differ-
ences) the AQLQ being 0.06 higher (95% CI −0.22 to 
0.35) in the intervention group, indicating better QOL. 
By 12 months, these figures were 0.35 (0.10 to 0.60) and 
0.21 (−0.09 to 0.51), respectively, and the between- group 
difference had risen to 0.18 (95% CI −0.21 to 0.56) higher 
in the intervention group. In the ACQ analysis, at the 
3- month analysis, the between- groups ACQ score was 0.14 
lower (95% CI −0.41 to 0.13) in the intervention group, 
indicating better control, and at 12 months, it was 0.14 
lower (95% CI −0.40 to 0.11). These findings indicate 
consistent trends to improvement in both asthma QOL 
and asthma control in the intervention group compared 
with the control. Full follow- up data are presented in 
table 2.
Adverse events
Adverse events were reported by GPs and nurses who 
contacted the study team to report both adverse and 
serious adverse events. Nine adverse events were reported 
(intervention n=6, usual care n=3). These were assessed 
by research team clinicians and all were considered 
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Table 1 Baseline demographic characteristics of study population per group.
M (SD)
Overall sample
(n=88)
Intervention group
(n=44)
Control group
(n=44)
Lost to follow- up 
(n=8)
Age 56.6 (15.2) 57.0 (14.2) 56.3 (16.2) 53.5 (12.11)
Female N (%) 53.0 (60.2) 27.0 (61.4) 26.0 (59.1) 6 (75)
BMI 29.5 (6.1) 28.9 (5.9) 30.1 (6.3) 32.7 (4.3)
Length of diagnosis 24.0 (17.5) 25.2 (17.2) 22.8 (17.8) 30 (18.9)
FEV1 2.5 (0.8) 2.6 (0.8) 2.5 (0.8) 2.40 (0.47)
% predicted FEV1 92.3 (16.0) 94.8 (16.0) 89.8 (15.8) 92.0 (12.9)
FEV1/FVC 76.6 (8.5) 77.1 (8.0) 76.1 (9.0) 74.9 (4.1)
Peak flow 421.2 (104.7) 421.3 (108.3) 421.1 (102.3) 420.6 (83.8)
Ethnicity
  White N (%) 84 (95.5) 42 (95.5) 42 (95.5) 7 (87.5)
  Other N (%) 4 (4.5) 2 (4.5) 2 (4.5) 1 (12.5)
Smoking status
  Current N (%) 9 (10.2) 7 (15.9) 2 (4.5) 2 (25.0)
  Former N (%) 29 (33.0) 13 (29.5) 16 (36.3) 3 (37.5)
  Never N (%) 50 (56.8) 24 (54.5) 26 (59.1) 3 (37.5)
Age left education 18.5 (5.3) 19.4 (7.0)* 17.7 (2.7) 20.4 (8.2)
  16 or under N (%) 40 (46.5) 18 (42.9) 22 (50.0) 4 (50.0)
  17–18 n (%) 22 (25.6) 9 (21.4) 13 (29.5) 1 (12.5)
  Above 18 (%) 24 (27.9) 15 (35.7) 9 (20.5) 3 (37.5)
Index of Multiple Deprivation
Mean Rank (median decile)
17 192 (5.5) 17 231 (6.5) 17 212 (5) 4505.5 (1.5)
AQLQ 4.81 (1.01) 4.85 (0.94) 4.78 (1.09) 4.26 (0.55)
ACQ 1.45 (0.80) 1.35 (0.66) 1.56 (0.91) 1.52 (0.73)
HADS- A 6.60 (4.47) 6.57 (3.87) 6.64 (5.04) 8.63 (3.9)
HADS- D 3.89 (3.57) 3.39 (3.07) 4.39 (3.99) 4.75 (4.4)
EQ- 5D- 5L 0.83 (0.19) 0.86 (0.15) 0.81 (0.22) 4 (50.0)
EQ- 5D- VAS 71.5 (18.2) 70.0 (19.3) 73.0 (17.2) 1 (12.5)
ICECAP- A 0.87 (0.18) 0.89 (0.12) 0.88 (0.16) 3 (37.5)
PEI 2.52 (1.23) 2.44 (1.09) 2.60 (1.37) 2.73 (1.0)
MARS- A 4.70 (1.05) 4.80 (0.90) 4.60 (1.20) 4.3 (0.8)
*Percentages are reported from 42 participants as 2 participants in the intervention group did not complete these data.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; EQ- 5D- 5L, EuroQol Five 
Dimensional Quality of Life; EQ- 5D- VAS, EuroQol- 5D Visual Analogue Scale; FEV1, forced expiratory volume; FVC, forced vital capacity; 
HADS- A, Hospital Anxiety and Depression Scale- Anxiety; ICECAP- A, Icepop Capability measure for Adults; MARS- A, Medication Adherence 
Rating Scale for Asthma; PEI, patient enablement instrument.
unlikely to be related to the study. Three were related 
to participant asthma (asthma exacerbation not leading 
to hospital admission, upper respiratory tract infection, 
sinusitis).
Three serious adverse events were reported (interven-
tion n=2, usual care n=1). These were considered unlikely 
to be related to the study and the condition (atrial fibrilla-
tion, open distal radius fracture, cardioversion).
healthcare utilisation outcomes
Data were collected from the retrospective notes reviews 
(conducted by practice nurses) from 83 participants, 
reported in table 3. Data were collected from 84 practices 
for seven participants, with four participants from one 
practice incomplete. The data quality check and subse-
quent examination by research team clinicians (MT) 
found that reviews completed by the practice nurses 
varied substantially in quality with varied levels of detail, 
and the quality of data achieved in this way was insuffi-
cient for a health economic analysis.
Comparisons between group count data were reported 
using a negative binomial model but given the issues 
with the reliability of the data, should be interpreted 
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Table 2 Three and 12 months follow- up data (corrected for baseline differences)
Measure
Intervention group
(n=36)
Control group
(n=44)
Difference between 
the intervention 
and control group 
controlling for 
baseline (95% CI)M (SD)
%>MCID*
improvement
% items 
complete M (SD)
%>MCID* 
improvement
% items 
complete
3 months
  AQLQ 5.51 (0.85) 47.2 82 5.30 (1.07) 47.7 100 0.06 (−0.22 to 0.35)
  ACQ 0.98 (0.65) 82 1.28 (0.87) 100 −0.14 (−0.41 to 0.13)
  HADS- A 6.75 (3.85) 82 7.07 (5.48) 100 −0.04 (−0.18 to 0.11)
  HADS- D 3.75 (2.82) 82 4.66 (4.99) 100 −0.02 (−0.16 to 0.13)
  PEI 2.71 (1.09) 82 2.90 (1.14) 100 −0.12 (−0.59 to 0.35)
  MARS- A 4.23 (0.70) 80 4.05 (0.74) 100 0.04 (−0.25 to 0.3)
  EQ- 5D- 5L 0.82 (0.19) 82 0.83 (0.20) 100 –
  ICECAP- A 0.87 (0.12) 82 0.84 (0.19) 100 –
12 months
  AQLQ 5.29 (0.98) 38.9 82 5.00 (1.25) 39.5 98 0.18 (−0.21 to 0.56)
  ACQ 1.00 (0.59) 82 1.26 (0.69) 98 −0.14 (−0.40 to 0.11)
  HADS- A 7.78 (3.94) 84 6.63 (4.91) 98 0.99 (0.16 to 2.15)
  HADS- D 3.81 (3.54) 84 4.19 (4.17) 98 0.22 (−0.97 to 1.41)
  PEI 2.46 (1.03) 84 2.61 (1.28) 98 −0.09 (−0.54 to 0.37)
  MARS- A 4.37 (0.81) 82 4.29 (0.85) 98 −0.09 (−0.43 to 0.25)
  EQ- 5D- 5L 0.83 (0.21) 82 0.80 (0.23) 98 –
  ICECAP- A 0.86 (0.13) 82 0.84 (0.20) 98 –
  FEV1 (litres) 2.75 (0.75) 57 2.43 (0.74) 80 0.03 (−0.05 to 0.10)
  FEV1/FVC 78.8 (6.58) 57 76.3 (9.29) 80 2.20 (−0.13 to 4.27)
% predicted 
FEV1
100.1 (14.8) 57 92.4 (13.8) 80 1.77 (−1.72 to 5.25)
Peak flow 450 (105) 57 417 (102) 80 15.29 (−6.27 to 36.86)
  BMI 28.7 (6.17) 64 31.1 (6.51) 86 −0.11 (−0.89 to 0.68)
*There was no difference in the number of patients who showed MCID improvement at 3 months (AQLQ, >0.5) across groups (47.2% in 
the intervention group compared with 47.7% in the control group). The same was true at 12 months (38.9% compared with 39.5%).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; EQ- 5D- 5L, EuroQol Five 
Dimensional Quality of Life; FEV1, forced expiratory volume; FVC, forced vital capacity; HADS- A, Hospital Anxiety and Depression Scale- 
Anxiety; ICECAP- A, Icepop Capability measure for Adults; MARS- A, Medication Adherence Rating Scale for Asthma; MCID, minimal 
clinically important difference; PEI, patient enablement instrument.
Table 3 Data on asthma- related medication use (during the study period)
Healthcare utilisation (N, IQR)
Mean (SD)
Intervention group Control group
12 months before 
study period
12 months after 
study period
12 months before 
study period
12 months after 
study period
SABA prescriptions 3 (2,6)
3.92 (3.48)
3 (1,6)
4.00 (3.72)
3 (2,5)
4.0 (3.89)
4 (2,6)
4.39 (3.81)
ICS prescriptions 5 (2,11)
6.72 (4.92)
4 (3,10)
6.15 (4.21)
6 (4,10)
7.41 (5.45)
6 (4,10)
7.34 (5.37)
Oral steroids prescriptions 0 (0,0)
0.31 (0.80)
0 (0,0)
0.36 (0.94)
0 (0,0)
0.43 (1.07)
0 (0,0)
0.23 (0.71)
Antibiotic prescriptions 0 (0,0)
0.33 (0.87)
0 (0,0)
0.28 (0.60)
0 (0,0)
0.52 (1.45)
0 (0,1)
0.16 (0.48)
ICS, Inhaled corticosteroids; SABA, Short- Acting Beta Agonist.
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cautiously. The prescription rate was approximately 8% 
higher for both SABA incidence rate ratio (IRR 1.08, 95% 
CI 0.82 to 1.43) and ICS (IRR 1.08, 95% CI 0.86 to 1.35) 
in the control group compared with the intervention 
group. Both groups had a low number of prescriptions 
for oral steroids, oral steroids and antibiotics, with only 
15 prescriptions in total for either of these medications, 
making between- group comparisons unreliable.
Due to unreliability of data, frequency of GP consulta-
tions, A&E admissions and hospitalisations have not been 
reported.
health economic outcomes
Both EQ- 5D- 5L and ICECAP- A had the same completion 
rates as other secondary measures completed at follow- up 
(see table 2).
Patients reported several programmes across both 
groups including gym, walking, yoga, sewing, language 
courses, physio and signing (see online supplementary 
file 2). There were no substantial differences in terms of 
numbers or costs although the sample size was small.
DISCuSSIOn
In line with our main research objectives, findings from 
our randomised controlled feasibility trial demonstrate 
that a full- size confirmatory trial to confirm effectiveness 
of MBM, a digital self- management intervention for adults 
in primary care with asthma is likely to be feasible and 
acceptable. Our trial procedures, intervention usage and 
data management were all feasible. There were also trends 
to improved asthma control and QOL in our underpow-
ered sample, so supporting the need for a definitive fully 
powered study. Our recruitment procedures recruited a 
specific patient sample (those impaired asthma- specific 
QOL) to target from a range of urban and rural practices.
Our sample varied in age with a relatively high mean 
(56 years) indicating that our DI can provide benefit to 
older adults. Both male and female adults were well repre-
sented in our trial. A notable proportion of our sample 
was obese (41%), in line with previous findings.11 Given 
that obesity is a risk factor for asthma, a larger trial could 
further improve effectiveness by providing more specific 
behavioural content for obese adults with asthma (such 
as tailored content to increase motivation to use weight 
loss- related lifestyle components in obese patients). 
Our sample was also predominantly white. Under- 
representation of minority ethnic groups in medical 
research in the UK is an ongoing issue12 and should be 
addressed in recruitment procedures in the full trial.
The feasibility of a full trial is supported by the effec-
tive completion of trial procedures. All patients who 
completed baseline measures were randomised. Comple-
tion of measures was good at both follow- up points (3 
months via post and 12 months at participants’ practice). 
Where participants were not able to attend a follow- up 
appointment at practices, they were satisfactorily followed 
up via post or telephone for main trial measures. Eight 
patients were lost to follow- up (four withdrew and four no 
longer responded to attempts to contact them). Notably, 
all eight patients lost to follow- up were in the interven-
tion group. It is possible that patients in the control 
group were more likely to maintain contact as they were 
only able to access the intervention on completion of 
12- month follow- up measures. Although lost to follow- up 
is low, it is important to consider whether that loss is 
differential. Those lost to follow- up were more likely to be 
more socioeconomically deprived, female, have a higher 
BMI, a longer time since diagnosis and a higher HADS- A 
and HADS- D score. It is possible that these patients would 
benefit from using MBM more than most, and there-
fore, we have proposed several ways to further increase 
trial efficacy. Automatic email intervention registration 
at baseline (patients cannot attend baseline appointment 
without enrolling on the intervention) would increase 
initial engagement and engagement with trial proce-
dures throughout duration of study. Online question-
naire completion during screening process would (1) 
screen patients who are unable to interact with online 
trial/intervention and therefore unable to benefit from 
the intervention (feasibility trial estimate=2%), and (2) 
streamline baseline/follow- up procedures.
Both health economic outcomes had high completion 
rates but did not suggest substantive change, similar to 
EQ- 5D measures in previous non- pharmacological self- 
management trials (such as Bruton et al8). It is possible 
that an alternative measure such as the Short Form 
12- item Survey31 in which participants consider the 
previous 2 weeks (whereas in the EQ- 5D they consider 
the immediate present) may be better suited to measure 
small yet valuable changes in well- being over a full trial. 
Our detailed mixed- methods process analysis explored 
issues of trial acceptability in more detail, and will be 
reported in a subsequent paper. A full trial of this non- 
pharmacological intervention should accurately capture 
‘non- medical’ costs (such as gym membership) that are 
likely to impact disease- specific QOL, as well as medical 
costs that would be affected by changes in healthcare 
utilisation.
Healthcare utilisation data were collected by practice 
nurses whose main role was to provide usual clinical care 
at the practices, using a manual to guide data collection, 
rather than by trained research nurses, and our quality 
check demonstrated that the data collection process used 
was unreliable some centres. We conclude that in a full 
subsequent study, these data should be collected from the 
medical record by a trained member of the study team 
(such as a trained research nurse), as has been success-
fully used in previous studies.8
Engagement with the intervention was slightly increased 
compared with a previous similar digital asthma self- 
management intervention19 at initial sign up (82% vs 76%) 
as well as maintaining a higher number of ongoing engage-
ment throughout the follow- up period (median 3 additional 
log ins vs 1), although our study used a broad primary care 
population while the RAISIN protocol primarily recruited 
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from areas of high deprivation. This finding demonstrates 
that the use of the person- based approach to develop the 
intervention resulted in an intervention that was acceptable 
and engaging to patients, even using a pragmatic meth-
odology in which patients self- registered at home instead 
of being registered by a GP during their baseline appoint-
ment. Participants accessed both pharmacological and non- 
pharmacological self- management content. We further 
explored the acceptability of the intervention to people 
with asthma in a mixed- methods process analysis which will 
be published separately.
Estimates of effect size demonstrated that participants 
who received the intervention and completed follow- up 
measures showed improved and clinically relevant QOL 
and asthma control. The order of magnitude of the mean 
between- group improvements in the patient reported 
measures of control (ACQ) and asthma- related QOL 
(AQLQ), although not statistically significant with the 
sample size of this feasibility study, was comparable to that 
reported in controlled studies of pharmacological32 and 
non- pharmacological8 interventions in asthma, and so 
justify a confirmatory study with a fully powered sample.
There was no suggestion of an effect on physiological 
measures of lung function. These results are in line with 
previous studies of behavioural self- management interven-
tions in primary care adults with asthma (such as BREATHE, 
RAISIN), and demonstrate the importance of interventions 
targeting outcomes that incorporate elements of functional 
well- being (disease- specific QOL, subjective symptoms), 
rather than solely focusing on objective, physiological 
measures that are not correlated with quality of life.
The effectiveness of our intervention could be further 
increased according to findings from our process eval-
uation. This analysis, which will be reported separately, 
broadly agrees with previous research19 in finding that 
many patients consider their asthma to be ‘well controlled’ 
despite having important levels of symptoms and QOL 
impairment on validated questionnaire. This implies that 
many people had become accustomed to their ongoing 
symptoms and had altered their life to try to reduce their 
impact, using denial as a coping mechanism. As a conse-
quence, the means of appropriately targeting and framing 
self- management interventions should be carefully consid-
ered in future work, focusing on maintaining good health 
rather than improving poor health. Some of our findings 
(such as the association between QOL improvement and 
ongoing intervention engagement) demonstrate that 
framing content as positive and not focusing on illness—for 
example ‘How to keep your breathing healthy’ rather than 
‘How to reduce asthma symptoms’ may lead to an accept-
able, engaging intervention that benefits this patient group.
There were some limitations to this small feasibility study. 
Although our researchers and statisticians were blind to 
group allocation, patients would have known that they were 
allocated to the intervention rather than the usual care 
control. This is common in complex behavioural interven-
tions. Furthermore, although we endeavoured to recruit 
participants across a broad demographic range, the reach 
of our intervention could be improved. While the reach 
of DIs improves as digital literacy increases nationally, care 
must be taken to ensure that ‘digital transformation’ of 
NHS services does not entrench healthcare inequality, by 
facilitating a ‘digital divide’ that fails to provide adequate 
health and social care to those who do not have the digital 
skills to benefit.
COnCluSIOn
Our findings demonstrate the feasibility of a new digital 
self- management intervention for asthma (MBM). Using 
the person- based approach to intervention development 
means that MBM is both acceptable and engaging for 
adults with asthma in primary care. MBM reflects the 
varied experiences of people with asthma, by including 
both non- pharmacological and pharmacological compo-
nents. Our data support the feasibility of moving towards 
a fully powered RCT, with only minor modifications to 
some trial procedures required.
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